<DOC>
	<DOCNO>NCT02661373</DOCNO>
	<brief_summary>Malaria infectious disease cause parasite pass human infected mosquito bite person . About 3.4 billion people live area world malaria regularly find . In many country , malaria one leading cause illness death . Despite , limited number drug , call antimalarial , use treat malaria increase report resistance exist antimalarials.. The purpose research study test new experimental antimalarial drug call SJ733 first assess safety , tolerability blood level healthy adult volunteer . PRIMARY OBJECTIVES : - To assess preliminary safety tolerability escalate dos antimalarial SJ733 healthy human volunteer . - To investigate pharmacokinetic ( PK ) profile escalate dos antimalarial SJ733 metabolite healthy human volunteer . - To identify dose SJ733 test separate Phase 1b human malaria challenge study . - To assess preliminary safety tolerability SJ733 healthy adult volunteer multiple oral dosing . - To assess pharmacokinetics SJ733 metabolite SJ506 multiple dose SJ733 healthy adult volunteer . SECONDARY OBJECTIVE : - To assess impact food intake pharmacokinetic profile antimalarial SJ733 .</brief_summary>
	<brief_title>First-in-Human Study Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor</brief_title>
	<detailed_description>This single site , Phase 1a , first-in-human , oral , primarily single-dose , dose escalation study ( + ) -SJ000557733 ( SJ733 ) healthy adult volunteer . SJ733 , investigational oral anti-malarial agent novel inhibitor Plasmodium falciparum plasma membrane protein ( PfATP4 ) . Subjects meet eligibility criterion enrol use leap frog , fix dose escalation design adaptive component 6 subject enrol per dose cohort . Following successful completion safety pharmacokinetic ( PK ) assessment result single-dose escalation portion study , three-dose cohort study undertaken . It include per day oral dose 3 consecutive day .</detailed_description>
	<criteria>Healthy adult ( certified comprehensive medical assessment include detailed history complete physical examination ) , male female , age 18 55 year age ( inclusive ) screen At least 50 kg weight body mass index ( BMI ) 18 34 kg/m^2 Able willing provide inform consent available followup plan duration study If female , child bear potential ( i.e . permanently sterilize hysterectomy bilateral oophorectomy least 6 month screen ; proper documentation require ] and/or postmenopausal define 12 month menses without alternative cause estradiol level &lt; 30 pg/mL folliclestimulating hormone level &gt; 40 IU/L screen ) Sexually active male must agree abstinent use condom duration study . Screening laboratory ( hematology , chemistry , venous methemoglobin level specify schedule evaluation ) within normal institutional range outside range , clinically significant opinion investigator . Inclusion Criteria Participants Singledose Cohort Only : : Agrees receive vaccination within 7 day prior Day 0 Day 7 . Agrees use nonprescription drug , include vitamin , antacid , herbal dietary supplement within 7 day prior Day 0 Day 7 . Acetaminophen may use dos ≤ 1 g/day , ibuprofen may use dos ≤ 1.2 g/day . Agrees use nicotine containing product screen Day 7 . Agrees consume alcohol 24 hour prior Day 0 Day 7 . Agrees eat pomegranate , grapefruit citrus fruit drink juice within 7 day prior Day 0 Day 7 . Agrees limit caffeine 200 mg Day 0 . Agrees eat drink ( except water ) 10 hour Day 0 visit water hour prior dose . Presence significant medical psychiatric condition opinion investigator precludes participation study . Clinically significant abnormality physical examination , opinion investigator , would preclude entry study . History significant illness within 2 week prior screen visit . Participants screen illness resolve two week . History clinically significant electrocardiogram abnormality clinically significant abnormality screen electrocardiogram . G6PD deficiency History hemolytic anemia methemoglobinemia History severe drug hypersensitivity include severe allergic reaction , anaphylaxis convulsion follow medication , vaccination infusion . History drug alcohol abuse 12 month prior screen evidence screen visit Use nicotine containing product within 30 day prior screen Positive blood test HBsAg , HCV , HIV1 Participation clinical study another investigational product within 30 day prior study enrollment , plan begin participation study . Employment direct supervision investigator study staff . Receipt vaccination within 7 day dose . Febrile illness within 48 hour dose Use prescription medication within 14 day prior study drug administration . Use nonprescription drug , include vitamin , antacid , herbal dietary supplement within 7 day prior study drug administration . Acetaminophen may use dos ≤ 1 g/day , ibuprofen may use dos ≤ 1.2 g/day . Consumption pomegranate , grapefruit citrus fruit juice within 7 day prior study drug administration . Use nicotine containing product screen study drug administration . Consumption alcohol within 24 hour prior study drug administration . Inclusion Criteria For participant multidose cohort : Agrees receive vaccination within 7 day prior Day 1 Day 10 . Agrees use nonprescription drug , include vitamin , antacid , herbal dietary supplement within 7 day prior Day 1 Day 10 . Acetaminophen may use dos ≤ 1 g/day , ibuprofen may use dos ≤ 1.2 g/day . Agrees use nicotine containing product screen Day 10 . Agrees consume alcohol 24 hour prior Day 1 Day 10 . Agrees eat pomegranate , grapefruit citrus fruit drink juice within 7 day prior Day 1 Day 10 . Agrees limit caffeine 200 mg Days 1 , 2 , 3 . Agrees eat drink ( except water ) 10 hour Days 1 , 2 , 3 visit water hour prior dosing day . Note : As single dose study , sexually active must agree abstinent use condom duration study ( Day 14 visit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antimalarial</keyword>
	<keyword>First-in-Human</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>